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Detection of anti-hepatitis C virus antibodies by ELISA using synthetic 
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A novel ELISA assay for the detection of anti-hepatitis C virus antibodies in the sera of infected individuals is describ- 
ed. This assay is based on a mixture of three 15-amino acid synthetic peptides encompassing regions of core and NS4 
proteins of hepatitis C virus~ Comparison with other available ELISA assays based on recombinant polypeptides 
shows that, short synthetic peptides have the advantage over some larger recombinant peptides by giving higher 
specificity without loss of sensitivity. 
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Hepatitis C virus (HCV) is the major, if not the only 
cause of non-A, non-B hepatitis (1). This infection fre- 
quently progresses to chronicity (2) with a high propor- 
tion of cases evolving to cirrhosis (3,4). In the Western 
world HCV is the leading cause of chronic hepatitis (2). 
Since the isolation and cloning of HCV by Choo et al. 
(5), many regions of its genome have been sequenced 
(6-12). This has shown that the HCV is an RNA virus 
with a genome of 9416 base pairs coding for a polypro- 
tein of 3010 amino acids. This polyprotein is processed 
by at least two proteases (one from the virus and one 
from the host) which free several proteins. These pro- 
teins, by analogy with those of flaviviruses and 
pestiviruses have been classified into structural (core, 
envelope or El, NS1/E2) and non-structural (NS2, NS3, 
NS4 and NS5) proteins. 
Kuo et al. (13) developed an ELISA assay based on 
a recombinant peptide (c-100) for the detection of anti- 
HCV antibodies in the sera of infected individuals. This 
assay (referred to as O1) was superceded by a second 
generation assay, also commercialized by ORTHO 
Diagnostics, based on recombinant fragments from 
structural and non structural regions of HCV (from now 
on 02). It has been reported that O1 detects anti-HCV 
antibodies late after infection (14) and also, may give 
false-positive results (15-19). In an attempt o solve 
these problems we developed an ELISA assay based on 
synthetic peptides (20). In this study the results of our 
assay are compared with those of O1, 02 and with a 
prototype developed by Welcome laboratories (from 
now on W) also based on recombinant antigens from 
structural and non structural regions of HCV. 
Materials and Methods 
Sera from patients and controls 
Blood donors sera (panel I): The sera from 221 blood 
donors were used as negative controls. 
Chronic non-A, non-B hepatitis era (panel 2): The 
sera from 150 patients fullfilling the following criteria: 
liver biopsy showing chronic persistent or chronic active 
hepatitis with or without cirrhosis, presence of raised 
serum alanine aminotransferase for more than 6 
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months, negativity for HBsAg, alcohol consumption 
less than 50 g/day, antinuclear antibodies negative or a 
titre lower than I/I00, absence of potential hepatotoxic 
drugs, normal evels of ceruplasmin and ot-l-antitrypsin. 
Chronic hepatitis B sera (panel 3): The sera from 98 
HBsAg positive patients with biopsy proven chronic 
hepatitis. 
Other sera (panel 4): 115 serum samples consecutively 
received in the laboratory from hemodyalisis patients 
and patients with hypertransaminasemia. 
assays, O1 and 02) were carried out according to the 
manufacturers (Ortho Diagnostics Systems, Raritan, 
New Jersey) instructions. 
Wellcome HCV assay 
This assay is an ELISA assay based on a recombinant 
viral antigen polypeptide named BHC10 encompassing 
regions from both the core and NS5 regions of the virus 
(Wellcome Diagnostics, Beckenham, Kent). It was car- 
ried out as described elsewhere (25). 
Peptide synthesis 
Peptides were synthesized by the solid-phase method 
of Merrifield (21) using the Fmoc alternative (22) with 
a manual multiple solid-phase synthesizer which can 
synthesize up to 96 independent peptides (23). The 
ninhydrin test of Kaiser (24) was used to monitor the 
coupling and deprotection steps. At the end of the syn- 
thesis, peptides were cleaved and deprotected followed 
by two washings with diethyl ether. They were used for 
the ELISA assays without further purification. 
RIBA assay 
The second generation RIBA assay from CHIRON 
was carried out according to the manufacturers in- 
structions. 
Serological markers of hepatitis B virus infection 
Serological markers of hepatitis B viral infection were 
investigated by RIA or ELISA with commercial 
reagents (Ausria II, Ausab, Corab, IMx HBsAg, Ausab 
EIA, IMx core; Abbott Laboratories, Chicago, Illinois). 
ELISA assay 
The ELISA plates (Nunc-Immunoplate MaxiSorp, 
Denmark) were coated at 4°C overnight with a mixture 
af peptides dissolved in 0.1 M sodium carbonate. This 
a, as done by adding 200 #l/well of this solution contain- 
ng 5 /zg/ml of each peptide. The plates were washed 
:hree times with phosfate-saline buffer (pH 7.2) contain- 
ng 0.1% of Tween-20 (PBST). The plates were then in- 
:ubated at 37°C for 45 min with 210 ttl/well of a 
[/21-serum dilution in PBST containing 1% powdered 
nilk (PBSTM). Two positive and three negative sera 
vere used as controls. After washing three times with 
~BST, 200 #l/well of 1/2000 biotinilated goat anti- 
roman antibody (Amersham, UK) and 1/500 strep- 
avidine peroxidase (Amersham, UK) in PBST was 
tdded and incubated at 37°C for 30 min. After 3 wash- 
ngs with PBST, the plates were developed in the dark 
,t room temperature for 15 min with 100 #l/well of a sol- 
ttion of 0.4 mg/ml of o-phenylendiamine in 0.05 M 
itrate (pH 5) buffer containing 0.014% hydrogen perox- 
:le. The reaction was stopped by adding 75 #l/well of 4 
sulphuric acid. The plates were read at 492 nm using 
Titertek Multiscan MK II. The cut off was calculated 
,y adding 0.4 optical density units to the average 
mding of the three negative control sera. 
'ommercial ORTHO HCV ELISA assays 
These assays (Ortho first and second generation 
;says, O1 and 02) were carried out according to the 
PCR analysis 
This analysis was carried out after reverse transcrip- 
tion of non-A, non-B viral sequences to cDNA. The 
amplification was done as described (25) using primers 
from the 5' non-coding region of the virus (26). 
Results 
In order to select linear epitopes useful for ELISA 
from the proteins coded by the HCV genome, over 300 
peptides of 15 amino acids in length were synthesized. 
These peptides encompass most regions of viral pro- 
teins. The core and envelope proteins were especially ex- 
plored with three sets of peptides to cover the whole 
sequence and each set differing from the other by a 
frame shift of 5 amino acids. 
To detect he peptides that were recognized by the 
majority of non-A, non-B sera and to discard those that 
were recognized by the immunoglobulins other than 
anti-HCV immunoglobulins, all peptides were tested by 
ELISA against he sera of 31 blood donors and 65 pa- 
tients with non-A, non-B chronic hepatitis. 
It was found that three peptides (two from core and 
one from NS4 proteins) taken together would allow the 
detection of anti-HCV antibodies in 95% of the non-A, 
non-B sera without cross-reacting with any of the 
healthy control sera. These results encouraged us to use 
a mixture of these three peptides to develop an ELISA 
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assay for the detection of anti-HCV antibodies in the 
sera. From now on this assay will be referred to as P. 
To compare the specificity and sensitivity of O1, 02, W 
and P assays, the sera were classified as follows: 
HCVposit ive serum: The serum is positive if the result 
is positive for at least one pair of the following assays: 
02, W, P, RIBA, PCR. 
HCV negative serum: The serum is negative if the 
result is negative for all assays or positive for only one 
of them. 
These definitions were used to classify the sera from 
four different panels. 
All the sera from panel 1 (221 blood donors) were 
classified as negative because they were negative to O1, 
02, W and P assays. 
The results obtained with panel 2 (non-A, non-B 
chronic hepatitis patients) are shown on Table l a. The 
sera were classified as 142 positive and 8 negative. The 
142 positive sera were detected by 02, W and P but only 
108 were detected by O1. Nineteen sera, from the 34 not 
detected by Ol but detected by 02, W and P, were tested 
by PCR. Eighteen out of the 19 (94.7%) sera tested were 
PCR positive. 
The results obtained with panel 3 (hepatitis B pa- 
tients) are shown on Table lb and Fig. 1. The sera were 
classified as 22 positive and 76 negative. Assays O1, 02, 
W and P gave 13, 13, 0 and 1 false-positive results, 
respectively because they attributed a positive result to 
a serum classified as negative. Similarly, O1, 02, W and 
P gave 9, I, 5 and 3 false-negative r sults. 
The results obtained with panel 4 (other sera) are 
shown on Table lc. The sera were classified as 56 
TABLE I 
Positive results assigned by O1, 02, W and P ELISA assays in three 
panels of sera. Concordance of these assignations with the final 
classification a of these sera 
Classification Number of positive sera to 
OI 02  W P 
(a) Panel 2: non-A, non-B hepatitis era 
142 HCV positive sera 108 142 142 142 
8 HCV negative sera 0 0 0 0 
(b) Panel 3: Hepatitis B sera 
22 HCV positive sera 13 21 17 19 
76 HCV negative sera 13 b 13 b 0 1 
(c) Panel 4: other sera 
56 HCV positive sera NT 54 52 53 
59 HCV negative sera NT 2 0 I 
aThe definitions for positive and negative anti-HCV sera are given in 
Results section. 
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Fig. 1. Comparison of the efficacy of 4 ELISA assays: O I, 02,  W and 
P in the detection of anti-HCV antibodies in the sera of 98 patients 
with chronic hepatitis B (panel 3). The number of positive and nega- 
tive results obtained with each assay are indicated in brackets under 
each bar. 
positive and 59 negative. Assays 02, W and P gave 2, 0 
and 1 false-positive and 2, 4 and 3 false-negative, respec- 
tively. 
Taking into account he results obtained with the four 
panels of sera (584 sera in total) we calculated the 
percentages of sensitivity and specificity of 02, W and 
P. These percentages are shown in Table 2. 
Discussion 
The results for non-A, non-B sera (Table la) show 
that assays 02, W and P have the same sensitivity. This 
sensitivity is much higher than O1. Clearly, the extra 
recombinant peptides added to O1 to give 02 have in- 
creased assay sensitivity by providing additional 
'recognizable' pitopes. 
With respect o assay specificity the results of Table 
1 and Fig. 1 indicate that both W and P are more 
specific than O1 and 02. Moreover, the similar lack of 
specificity of O1 and 02 found in panel 3 (false-positives 
shown in Fig. 1 and Table l b) might be due to a cross- 
TABLE 2 
Comparison of the sensitivity and specificity of 02. W and P ELISA 
assays 
Assays 
02 W P 
Sensitivity 98.6% 95.9% 97.3% 
Specificity 95.9% 100% 99.4% 
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reaction of antigen c-100 (which is used in O1 and 02) 
with antibodies other than anti-HCV antibodies. This 
suggests that a similar epitope might be present in the 
proteins of hepatitis B virus and the c-100 antigen. To 
explore this hypothesis a sequence homology between c- 
100 and the different proteins from HBV was looked 
for. The peptide LQTLPANPPPAS, amino acids 75-87 
of pre-S1 protein of ayw HBV serotype (one of the two 
most common serotypes in Spain) were found to be very 
similar to the peptide LSTLPGNPAIAS, amino acids 
1778-1789 from the NS4 region of HCV and contained 
by col00 antigen. Indeed, eight out of 12 amino acids are 
identical in both peptides. These two peptides were syn- 
thesized and used as antigens in an ELISA assay against 
the false-positive of O1 and 02 of panel 3. Since it was 
found that 42% of these sera recognized both peptides, 
we believe that these antibodies might be responsable 
for some of the false positive results observed when 
using the O1 and 02 assays. 
An ELISA assay based onsynthetic peptides has been 
recently published by Hosein et al. (27). We have not 
had access to this assay and for this reason were unable 
to compare it with our own. Moreover, since their re- 
sults are only compared with O1, which has low sensitiv- 
ity and poor specificity, no conclusions could be drawn 
concerning its relative value with respect o 02, W and 
P assays. 
Because of their size, recombinant protein fragments 
have the advantage of containing a potentially high 
number of 'recognizable' pitopes. For similar reasons 
they also have the risk of encompassing epitopes that 
might cross-react with other antibodies not elicited by 
the HCV and give false-positive r sults - -  antibodies in- 
duced by a common antigen like those from influenza 
virus for example - - .  Moreover, recombinant peptides 
are usually expressed as fusion peptides with a protein 
that is easily expressed. This enhances the possibility of 
cross-reactivity even more. Thus, it has been reported 
(16) that superoxidismutase (SOD, the fusion protein 
with which the c-100 fragment of the O1 assay is ex- 
pressed) might be responsible for the false-positive 
results of O1 in the case of autoimmune chronic active 
hepatitis. 
Unlike recombinant polypeptides, short synthetic 
peptides (of around 15 amino acids) cannot detect an- 
tibodies induced against most conformational epitopes 
of the antigen. However, since they restrict antibody 
recognition to smaller molecules, the risk of possible 
cross-reaction with undesirable antibodies i diminish- 
ed. Indeed, as shown in Table 2, anti-HCV antibodies 
can be detected by ELISA with short synthetic peptides 
83 
with similar sensitivity and better specificity than with 
some large recombinant antigens. 
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